@article{article_393435, title={The evaluation of JAK2V617F mutation and thromboembolism in chronic myeloproliferative neoplasia patients; a single center experience}, journal={Pamukkale Medical Journal}, pages={196–200}, year={2014}, author={Çağlıyan, Gülsüm Akgün and Bilgir, Oktay}, keywords={Myeloproliferative Neoplasm, JAK2 mutation, Thromboembolism}, abstract={OBJECTIVE: Myeloproliferative neoplasms are clonal diseases that associated with hemostasis and thrombosis anomalies as well as progression to acute leukemia. PV, ET and IMF are bcr- abl negative myeloproliferative neoplasmsMETHODS: In this study, we evaluated 128 bcr-abl negative CMPN patients, was followed in Izmir Bozyaka Traning and Research Hospital, Department of Hematology, in between 2008 and 2013. We investigated; demographic and laboratory information, the state of JAK2V617F mutation and therapies, by retrospectively. RESULTS: Of the total of 128 patients, 63 patients were female and 65 were male. All of patients’s ages were between 23-87 years old. Median age was 65 years old. 87 of patients had JAK2V617F positive. 41 patients had JAK2V617F negative. JAK2V617F positive (37/87) patients and JAK2V617F negative patients (13/87) had thrombotic events. It was significant clinically and statistically in JAK2V617F mutation positive patients who had more thrombotic events (p=0.003). The most of thrombotic events was coroner arter diseases (20/50).CONCLUSION: In conclusion, JAK2V617F gene mutation is an important finding for diagnosis and complication in CMPN patients.}, number={3}, publisher={Pamukkale University}